Improvement of myocardial injury and gut microbiota disturbance in type 2 diabetic mice by inulin with various degrees of polymerization  

作　　者：Siqiang Jia Jianpeng Li Bin Yu Mengjie Li Bo Cui 

机构地区：[1]State Key Laboratory of Biobased Material and Green Papermaking,Qilu University of Technology,Shandong Academy of Sciences,Jinan,250353,China [2]School of Food Science and Engineering,Qilu University of Technology,Shandong Academy of Sciences,Jinan,Shandong,250353,China

出　　处：《Food Bioscience》2023年第1期995-1004,共10页食品生物科学（英文）

基　　金：supported by the National Key Research&Development Program in China(Grant No.2019YFD1002704);Shandong Major Projects of Independent Innovation(2019JZZY010722);Funds for Innovation Team of Jinan(2018GXRC004);Bohai Sea Granary Science and Technology Demonstration Project(2019BHLC002);Special Funds for Taishan Scholars Project are acknowledged.

摘　　要：This study is to explore the effects of low-performance inulin(SI,DP<10)and high-performance inulin(HI,DP>10)on myocardial injury in type 2 diabetic mice fed a high-fat diet(HFD)and its underlying mechanism.Six weeks of supplementation of type 2 diabetic mice with HI significantly improved blood glucose,insulin,and triglyceride levels in comparison with SI(p<0.05).HI had more advantageous effects in ameliorating myocardial injury by suppressing TNF-α,IL-1β,and CK-MB and promoting SDF-1βthan SI.Compared to SI,HI more significantly reduced the abundance of Firmicutes from 60.5%to 36.3%in type 2 diabetic mice fed a HFD and increased the abundance of Muribaculum,Blautia and Ruminococcaceae UCG-011 at the genus level(p<0.05).Metabolomics revealed that both SI and HI supplementation regulated tryptophan metabolism,bile acid metabolism,sphingolipid metabolism,and arachidonic acid metabolism,whereas HI supplementation increased prostaglandin h2 compared to SI.In summary,HI exhibited superior positive regulation of myocardial injury and gut microbiota dysfunction compared to SI.

关 键 词：INULIN Myocardial injury Type 2 diabetic mice Gut microbiota Fecal metabolome 

分 类 号：R542.2[医药卫生—心血管疾病]